Trial Profile
A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared With Physician's Best Choice in HER2-Negative Breast Cancer Patients With Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD)
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Apr 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel trevatide (Primary) ; Capecitabine; Eribulin; Methotrexate
- Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; Meningeal carcinomatosis
- Focus Registrational; Therapeutic Use
- Acronyms ANGLeD
- Sponsors AngioChem
- 19 Apr 2023 Planned primary completion date changed from 1 Mar 2024 to 1 Dec 2024.
- 19 Apr 2023 Planned initiation date changed from 1 Sep 2022 to 1 Dec 2023.
- 20 Apr 2022 Planned End Date changed from 1 Sep 2024 to 1 Dec 2024.